Long-term disease control of a non-operable neuroendocrine tumor of the lung with lanreotide: a case study.
Bronchopulmonary neuroendocrine tumors (NETs) are malignant tumors that represent approximately 20% of all lung cancers. The therapeutic option for advanced or metastatic bronchopulmonary NETs is mainly palliation of symptoms; options need to be individualized and, therefore, rely on the knowledge of multidisciplinary teams. Somatostatin analogs have been widely used in NETs for control of hormonal syndromes and are currently under evaluation for their antiproliferative activity. Here, we present a case of NET of the lung, for which we achieved long-term disease control with a treatment comprising the somatostatin analog lanreotide Autogel(®) in a patient with limited therapeutic options due to considerable comorbidity, while preserving his quality of life.
Department of Medical Oncology, Ziekenhuisnetwerk Antwerpen, Antwerp, Belgium.
F
F
Van Fraeyenhove
E
E
De Droogh
N
N
Meireson
D
D
Galdermans
C
C
Goor
F
F
Van Acker
C
C
Mattelaer
V
V
De Ruyter
D
D
Schrijvers
Carcinoid; Lung; Neuroendocrine tumor